Journal of Clinical Immunology

, Volume 32, Issue 4, pp 802–808

Type17 T-cells in Central Nervous System Autoimmunity and Tumors


DOI: 10.1007/s10875-012-9686-z

Cite this article as:
Okada, H. & Khoury, S.J. J Clin Immunol (2012) 32: 802. doi:10.1007/s10875-012-9686-z


Interleukin-17 (IL-17) producing Type17 T-cells, specifically T-helper (Th)17 cells reactive to central nervous system (CNS) autoantigens, manifest a higher migratory capability to the CNS parenchyma compared with other T-cell subpopulations due to their ability to penetrate the blood brain barrier (BBB). In the field of cancer immunotherapy, there are now a number of cell therapy approaches including early studies using T-cells transduced with chimeric antigen receptors in hematologic malignancy, suggesting that the use of T-cells or genetically modified T-cells could have a significant role in effective cancer therapy. However, the successful application of this strategy in solid tumors, such as CNS tumors, requires careful consideration of critical factors to improve the tumor-homing of T-cells. The current review is dedicated to discuss recent findings on the role of Type17 T-cells in CNS autoimmunity and cancer. The insight gained from these findings may lead to the development of novel therapeutic and prophylactic strategies for CNS autoimmunity and tumors.


Th17IL-17autoimmunitycentral nervous systemmultiple sclerosisgliomasadoptive transfer therapy

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Neurological SurgeryUniversity of Pittsburgh School of MedicinePittsburghUSA
  2. 2.Brain Tumor ProgramUniversity of Pittsburgh Cancer InstitutePittsburghUSA
  3. 3.Center for Neurologic Diseases, Brigham and Women’s HospitalHarvard Medical SchoolBostonUSA
  4. 4.American University of BeirutBeirutLebanon
  5. 5.Neurological Surgery, Surgery and Immunology, Clinical and Translational Science InstituteUniversity of Pittsburgh School of MedicinePittsburghUSA